Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

被引：47

作者：

Athyros, Vasilios G. ^{[1
]}

Tziomalos, Konstantinos ^{[2
]}

Daskalopoulos, Georgios N. ^{[3
]}

Karagiannis, Asterios ^{[1
]}

Mikhailidis, Dimitri P. ^{[4
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[2] Aristotle Univ Thessaloniki, AHEPA Hosp, Sch Med, Propedeut Dept Internal Med 1, Thessaloniki, Greece

[3] Larissa Hosp, Cardiol Clin, Larisa, Greece

[4] UCL, Univ Coll Med Sch, Royal Free Hosp Campus, Dept Clin Biochem,Vasc Prevent Clin, London, England

来源：

ANNALS OF MEDICINE | 2011年 / 43卷 / 03期

关键词：

Cardiovascular disease; clinical benefit; liver enzymes; non-alcoholic fatty liver disease; statin; CORONARY-HEART-DISEASE; TYPE-2; DIABETIC-PATIENTS; C-REACTIVE PROTEIN; RENAL-FUNCTION; GREEK ATORVASTATIN; EVALUATION GREACE; METABOLIC SYNDROME; STEATOHEPATITIS; CHOLESTEROL; HYPERLIPIDEMIA;

D O I：

10.3109/07853890.2011.561363

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) share common risk factors and may have a parallel course. Statin treatment alone or in combination with other drugs has a substantially beneficial effect on CVD morbidity and mortality. The question was if these regimens were harmful for the liver. Mounting data suggest that statin monotherapy or statin-based treatments are safe in patients with NAFLD and can improve liver tests and liver ultrasonographic evidence of NAFLD. Recent data suggest that statin-based therapies are beneficial to the liver and at the same time reduce CVD morbidity and mortality in patients with NAFLD more than in subjects without it. These findings suggest that with statins we are able to get two birds with one stone.

引用

页码：167 / 171

页数：5

共 57 条

[1] Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? [J].

Ahmed, Mohamed H. ;

Byrne, Christopher D. .

DRUG DISCOVERY TODAY, 2010, 15 (15-16) :590-595

[2] New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) [J].

Ali, Rafeeq ;

Cusi, Kenneth .

ANNALS OF MEDICINE, 2009, 41 (04) :265-278

[3] Current best treatment for nonalcoholic fatty liver disease [J].

Angulo, P .

EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) :611-623

[4]

Athyros VG, 2010, CURR PHARM DESIGN, V16, P3839, DOI 10.2174/138161210794455085

[5] Do we need to consider inflammatory markers when we treat atherosclerotic disease? [J].

Athyros, Vasilios G. ;

Kakafika, Anna I. ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ATHEROSCLEROSIS, 2008, 200 (01) :1-12

[6] Statins and renal function. Is the compound and dose making a difference? [J].

Athyros, Vasilios G. ;

Karagiannis, Asterios ;

Kakafika, Anna ;

Elisaf, Moses ;

Mikhailidis, Dimitri P. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (03) :963-964

[7] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Didangelos, Triandafillos P. ;

Giouleme, Olga I. ;

Liberopoulos, Evangelos N. ;

Karagiannis, Asterios ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Burroughs, Andrew K. ;

Elisaf, Moses S. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :873-883

[8] Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Gossios, Thomas D. ;

Griva, Theodora ;

Anagnostis, Panagiotis ;

Kargiotis, Konstantinos ;

Pagourelias, Efstathios D. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

LANCET, 2010, 376 (9756) :1916-1922

[9] Lipid-lowering agents and new onset diabetes mellitus [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (12) :1965-1970

[10] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Mercouris, BR ;

Athyrou, VV ;

Symeonidis, AN ;

Basayannis, EO ;

Demitriadis, DS ;

Kontopoulos, AG .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228

← 1 2 3 4 5 6 →